Ablynx has commenced pre-clinical development of ALX-0962, an anti-immunoglobulin E (IgE) nanobody, to treat severe allergic asthma.
ALX-0962 comprises anti-IgE nanobody with a dual mode of action and a serum albumin binding nanobody for in-vivo plasma half-life extension.
Go deeper with GlobalData
The company is developing the anti-IgE nanobody as a next-generation biologic against severe allergic asthma with important potential benefits compared to existing therapeutics.
Ablynx believes ALX-0962 has the potential to exhibit a better safety profile with faster onset of action, along with convenient dosing regimens.
Ablynx chairman and CEO Dr Edwin Moses said the biologic is expected to enter the clinic in the second half of 2014.
“Severe allergic asthma is an important condition and represents a substantial segment of the total asthma market that currently has a total value of $14.7bn,” Moses said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Due to the nanobody’s unique and dual mode of action, we believe ALX-0962 could take an important share of this very large market not least by offering a treatment option to patients not eligible for currently-available IgE-inhibiting drugs.”
The company expects to begin Phase I development in the second half of 2014.
Image: Asthma obstruction of the lumen of the bronchiole. Photo: Courtesy of Yale Rosen.
